Rahmer Peter's Form 4 filing
Relay Therapeutics, Inc. (RLAY) · filed Jan 29, 2026
- Accession no.
- 0001193125-26-029412
- Filed
- Jan 29, 2026
- Trade date
- Dec 31, 2025-Jan 28, 2026
- Filing delay
- 29 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $100.5K. It was filed 29 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rahmer PeterCIK 0001959229 | Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Common Stock | AGrant or awardAcquired | +994 | $2.99F2 | +$2,972.06 | 338,463 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −11,684 | $7.62 | −$89,032.08 | 277,964 | Direct | |
| Jan 28, 2026 | Common Stock | SSaleDisposed | −1,354 | $8.45 | −$11,441.3 | 276,610 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Corporate Development Officer